Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (GATEWAY)

9 maj 2026 uppdaterad av: Chen Chunyan, Sun Yat-sen University

Neoadjuvant Becotatug Vedotin (Anti-EGFR ADC) Combined With Pucotenlimab (Anti-PD-1) in Patients With Resectable Recurrent Head and Neck Squamous Cell Carcinoma Who Progressed on Prior PD-1/PD-L1 Inhibitor and Platinum-Based Therapy: A Prospective, Single-Arm, Multi-Center, Phase II Clinical Trial

This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1 monoclonal antibody) in patients with resectable recurrent head and neck squamous cell carcinoma (rHNSCC) who have progressed on prior PD-1/PD-L1 inhibitor and platinum-based therapy.

A total of 42 EGFR-positive patients will be enrolled using Simon's two-stage design across 11 centers in China (Stage 1: 25 patients; Stage 2: 17 additional patients with 5% dropout). Enrolled patients will receive 3 cycles of neoadjuvant becotatug vedotin (2.3 mg/kg, IV, Q3W) plus pucotenlimab (3 mg/kg, IV, Q3W), followed by salvage surgery (3-4 weeks later), adjuvant radiotherapy +/- chemotherapy per NCCN/CSCO guidelines, and pucotenlimab maintenance therapy (3 mg/kg, Q3W) for up to 12 cycles or until disease progression or unacceptable toxicity.

The primary endpoint is major pathological response (MPR) rate. The null hypothesis MPR rate is 14% (historical data) and the target MPR rate is 30% (alpha=0.05, power=0.8, one-sided). Secondary endpoints include objective response rate (ORR), pathological complete response (pCR), survival outcomes, quality of life, and safety.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Recurrent head and neck squamous cell carcinoma (rHNSCC) remains a significant clinical challenge, with recurrence rates of 40-60% after curative treatment. Salvage surgery is the standard of care, yet approximately 50% of patients experience re-recurrence within 2 years. For patients who have progressed on prior PD-1 inhibitor and platinum-based therapy, effective treatment options are extremely limited.

Becotatug vedotin is a novel anti-EGFR antibody-drug conjugate (ADC) that has demonstrated significant anti-tumor activity in HNSCC, with an ORR of 40% in Phase Ia/Ib and 43% in the post-immunotherapy Phase II study. Pucotenlimab (HX008) is a PD-1 inhibitor with an extended half-life (T1/2 = 21.76 days). Phase I/II data showed the combination achieved ORR of 60% in HNSCC with manageable toxicity.

This study investigates neoadjuvant becotatug vedotin plus pucotenlimab in resectable rHNSCC after immunotherapy progression.

TREATMENT REGIMEN:

  1. Neoadjuvant: Becotatug vedotin 2.3 mg/kg IV + Pucotenlimab 3 mg/kg IV, Q3W, 3 cycles
  2. Surgery: Salvage surgery 3-4 weeks after neoadjuvant completion
  3. Adjuvant: IMRT (60-66 Gy/30f) +/- platinum-based chemotherapy per NCCN/CSCO
  4. Maintenance: Pucotenlimab 3 mg/kg IV Q3W for 12 cycles or until progression/toxicity

Simon's two-stage design: Stage 1 (25 patients, >=3 MPR required) to Stage 2 (17 additional, total 42). H0 MPR=14%, H1 MPR=30% (alpha=0.05, power=0.8).

Studietyp

Interventionell

Inskrivning (Beräknad)

42

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Chunyan Chen, MD, PhD
  • Telefonnummer: +86 (020) 87342926

Studieorter

    • Guangdong
      • Foshan, Guangdong, Kina
        • The First People's Hospital of Foshan
      • Guangzhou, Guangdong, Kina
        • Sun Yat-sen University Cancer Center
      • Guangzhou, Guangdong, Kina
        • Guangdong Provincial People's Hospital
      • Guangzhou, Guangdong, Kina
        • Guangzhou First People's Hospital
      • Guangzhou, Guangdong, Kina
        • ZhuJiang Hospital of Southern Medical University
      • Guangzhou, Guangdong, Kina
        • The third affiliated hospital of Sun Yat-Sen University
      • Guangzhou, Guangdong, Kina
        • Cancer Hospital of Guangzhou Medical University
      • Qingyuan, Guangdong, Kina
        • Qingyuan People's Hospital
      • Shantou, Guangdong, Kina
        • Cancer Hospital of Shantou University Medical College
      • Shenzhen, Guangdong, Kina
        • Shenzhen Second People's Hospital
      • Zhanjiang, Guangdong, Kina
        • Affiliated Hospital of Guangdong Medical University
    • Jiangxi
      • Ganzhou, Jiangxi, Kina
        • Ganzhou Cancer Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

INCLUSION CRITERIA:

  1. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  2. Age 18-75 years at time of consent
  3. Histologically or cytologically confirmed recurrent head and neck squamous cell carcinoma
  4. Disease progression after prior treatment including both PD-1/PD-L1 inhibitor and platinum-based therapy (combined or sequential)
  5. EGFR protein expression positive by immunohistochemistry (IHC), with no EGFR-targeted therapy within 6 months prior to enrollment
  6. Willing to provide archived tumor tissue or undergo fresh tumor biopsy for EGFR testing
  7. At least one measurable extracranial lesion per RECIST v1.1; previously treated lesions must demonstrate clear progression 3 or more months after last local treatment
  8. Resectable disease with no distant metastasis, as assessed by a multidisciplinary team
  9. Adequate organ function within 7 days prior to enrollment: ANC at least 2.0 x 10^9/L, platelet count at least 100 x 10^9/L; total bilirubin less than 1.5 x ULN, ALT/AST less than 2.5 x ULN; serum creatinine less than 1.5 x ULN
  10. Signed informed consent prior to any study-specific procedures
  11. Life expectancy greater than 3 months
  12. Effective contraception during study and for 6 months after last dose

EXCLUSION CRITERIA:

  1. History of other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ)
  2. Comorbidities requiring long-term immunosuppressive therapy or corticosteroids at immunosuppressive doses
  3. Immunodeficiency or history of organ transplantation (including interstitial pneumonia, hepatitis, nephritis, hyperthyroidism, hypothyroidism)
  4. HIV/AIDS; untreated active hepatitis B (HBV-DNA at least 500 IU/mL); hepatitis C (HCV-RNA above detection limit); or HBV/HCV co-infection
  5. High-dose systemic corticosteroids within 4 weeks prior to enrollment
  6. Pregnant or lactating women; fertile patients not using effective contraception
  7. Laboratory values not meeting inclusion criteria within 7 days
  8. Significantly impaired cardiac, hepatic, pulmonary, renal, or bone marrow function
  9. Severe uncontrolled comorbidities or active infections
  10. Concurrent participation in other clinical trials
  11. Refusal or inability to sign informed consent
  12. Other contraindications to study treatment as determined by the investigator
  13. Psychiatric disorders or mental illness resulting in lack of legal capacity

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Neoadjuvant Becotatug Vedotin + Pucotenlimab
Becotatug vedotin as one of the drugs used in neoadjuvant therapy.
Pucotenlimab as one of the drugs used in neoadjuvant therapy.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Major Pathological Response Rate (MPR)
Tidsram: At time of surgery, approximately 12 weeks after enrollment
Proportion of patients with less than or equal to 10% viable tumor cells in the surgically resected specimen after neoadjuvant therapy, assessed by central pathology review.
At time of surgery, approximately 12 weeks after enrollment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate (ORR)
Tidsram: After 3 cycles of neoadjuvant therapy, approximately 9 weeks
Proportion of patients achieving complete response (CR) or partial response (PR) per RECIST v1.1.
After 3 cycles of neoadjuvant therapy, approximately 9 weeks
Pathological Complete Response Rate (pCR)
Tidsram: At time of surgery
Proportion of patients with no residual viable tumor cells in the surgically resected specimen.
At time of surgery
Median Overall Survival (mOS)
Tidsram: Up to 60 months from enrollment
Time from enrollment to death from any cause.
Up to 60 months from enrollment
Median Progression-Free Survival (mPFS)
Tidsram: Up to 60 months from enrollment
Time from enrollment to disease progression per RECIST v1.1 or death from any cause.
Up to 60 months from enrollment
Duration of Response (DoR)
Tidsram: Up to 60 months
Time from first documented CR or PR to disease progression or death.
Up to 60 months
6-Month Progression-Free Survival Rate
Tidsram: 6 months after end of treatment
Proportion of patients alive without disease progression at 6 months after completion of study treatment.
6 months after end of treatment
12-Month Progression-Free Survival Rate
Tidsram: 12 months after end of treatment
Proportion of patients alive without disease progression at 12 months after completion of study treatment.
12 months after end of treatment
Incidence of Adverse Events (AEs)
Tidsram: Through study completion, up to 90 days after last dose
Safety assessed per NCI CTCAE v5.0. Incidence and severity of all AEs, treatment-emergent AEs, and immune-related AEs.
Through study completion, up to 90 days after last dose
Incidence of Serious Adverse Events (SAEs)
Tidsram: Through study completion, up to 90 days after last dose
Incidence of serious adverse events assessed per CTCAE v5.0.
Through study completion, up to 90 days after last dose
Quality of Life - DASS-21
Tidsram: Baseline, during treatment, and follow-up through 12 months
Depression, Anxiety, and Stress Scale (21-item version).
Baseline, during treatment, and follow-up through 12 months
Quality of Life - PTGI
Tidsram: Baseline and follow-up through 12 months
Post-Traumatic Growth Inventory.
Baseline and follow-up through 12 months
Quality of Life - EORTC QLQ-C30
Tidsram: Baseline, during treatment, and follow-up through 12 months
EORTC Quality of Life Questionnaire Core 30.
Baseline, during treatment, and follow-up through 12 months
Stigma Scale
Tidsram: Baseline and follow-up through 12 months
Chronic disease stigma assessment.
Baseline and follow-up through 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Xuekui Liu, MD, PhD, Sun Yat-sen University Cancer Center
  • Studiestol: Chunyan Chen, MD, PhD, Sun Yat-sen University Cancer Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 maj 2026

Primärt slutförande (Beräknad)

1 november 2027

Avslutad studie (Beräknad)

1 maj 2029

Studieregistreringsdatum

Först inskickad

9 maj 2026

Först inskickad som uppfyllde QC-kriterierna

9 maj 2026

Första postat (Faktisk)

15 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera